The Weekly Summary

OK-victimsMay 20th – May 27th  

In general news, a British soldier was brutally beheaded by too radical Islamic terrorists in London. In the U.S., one of the largest tornados in history leveled a suburb of Oklahoma City, killing children in an elementary school, and Memorial Day was celebrated under extreme weather (snow in New York and floods in Texas).

In healthcare business news, Bausch & Lomb could be acquired by Valeant (VRX) for $9, while Actavis (ACT) plans to buy Warner Chilcott for $8.5 B. Recall, VRX and ACT almost merged. Pfizer (PFE) plans to sell the remaining equity in animal health Zoetis (ZTS). Lastly, the Supreme Court will hear a case relating the a Medtronic patent.

On the data front, Euro PCR generated little new data on renal denervation, TAVI, or Bioabsorbable stents. AcelRX’s (ACRX) Sufentanil NanoTab PCA System to treat postoperative pain met endpoints, sending shares higher. Xenoport (XNPT) cancelled the MS program after an anti-spasticity drug arboclofen failed. Lastly, PFE also halted study of inotuzumab for NHL.

From the FDA, an AdCom voted to approved Merck’s (MRK) new sleep drug suvorexant.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.